HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RLS-0071

peptide inhibitor of complement C1

Also Known As:

PA-dPEG24

Networked: 4 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 84029
  - RLS-0071: 4

Experts

1.	Cunnion, Kenji: 2 articles (05/2023 - 01/2021)
2.	Hair, Pamela: 2 articles (05/2023 - 01/2021)
3.	Cunnion, Kenji M: 2 articles (01/2022 - 01/2021)
4.	Krishna, Neel K: 2 articles (01/2022 - 01/2021)
5.	Ellis, Alexander: 1 article (05/2023)
6.	Goss, Jessica M: 1 article (05/2023)
7.	Kumar, Parvathi S: 1 article (05/2023)
8.	Thienel, Ulrich: 1 article (05/2023)
9.	Parker, Grace A: 1 article (01/2022)
10.	Bass, Thomas: 1 article (01/2021)

Related Diseases

1.	Acute Lung Injury 01/01/2022 - "RLS-0071 has been tested in various ex vivo and in vivo systems and has shown promise for the treatment of both immune-mediated hematological diseases where alterations in the classical complement pathway plays an important pathogenic role as well as in models of tissue-based diseases such as acute lung injury and hypoxic ischemic encephalopathy driven by both complement and neutrophil-mediated pathways (i.e., MPO activity and NET formation). "
2.	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 01/01/2022 - "RLS-0071 has been tested in various ex vivo and in vivo systems and has shown promise for the treatment of both immune-mediated hematological diseases where alterations in the classical complement pathway plays an important pathogenic role as well as in models of tissue-based diseases such as acute lung injury and hypoxic ischemic encephalopathy driven by both complement and neutrophil-mediated pathways (i.e., MPO activity and NET formation). "
3.	Hypothermia 01/01/2021 - "RLS-0071 alone or in combination with hypothermia improved both short-term and long-term memory. " 01/01/2021 - "MRI neuroimaging demonstrated that RLS-0071 in combination with hypothermia reduced lesion volume at 24 hours (P<0.05) as well as decreased T2 signal at day 21 in combination with hypothermia (P<0.01). " 01/01/2021 - "On histological evaluation, RLS-0071 showed neuronal protection in combination with hypothermia (P = 0.048) in addition to reducing C1q levels in the brain at 1hr (P = 0.01) and at 8 hr in combination with hypothermia (P = 0.005). " 01/01/2021 - "Rat pups subject to hypoxia-ischemia insult received one of 4 interventions including normothermia, hypothermia and RLS-0071 with and without hypothermia. "
4.	Hematologic Diseases (Blood Diseases) 01/01/2022 - "RLS-0071 has been tested in various ex vivo and in vivo systems and has shown promise for the treatment of both immune-mediated hematological diseases where alterations in the classical complement pathway plays an important pathogenic role as well as in models of tissue-based diseases such as acute lung injury and hypoxic ischemic encephalopathy driven by both complement and neutrophil-mediated pathways (i.e., MPO activity and NET formation). "
5.	Ischemia 01/01/2021 - "Rat pups subject to hypoxia-ischemia insult received one of 4 interventions including normothermia, hypothermia and RLS-0071 with and without hypothermia. "

Related Drugs and Biologics

1.	Complement System Proteins (Complement)
2.	Peptides (Polypeptides)
3.	Peroxidase (Myeloperoxidase)
4.	Complement C1 (Complement 1)
5.	Antiviral Agents (Antivirals)